Immunogenicity of a U.S.-Licensed Meningococcal Serogroup B Vaccine (Trumenba) in Adults at Increased Risk of Meningococcal Disease Because of Occupational Exposure

Trial Profile

Immunogenicity of a U.S.-Licensed Meningococcal Serogroup B Vaccine (Trumenba) in Adults at Increased Risk of Meningococcal Disease Because of Occupational Exposure

Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 04 Oct 2016

At a glance

  • Drugs PF 5212366 (Primary)
  • Indications Meningococcal infections
  • Focus Pharmacodynamics
  • Most Recent Events

    • 28 Sep 2016 Planned number of patients changed from 14 to 18.
    • 28 Sep 2016 Planned End Date changed from 1 May 2016 to 1 May 2017.
    • 28 Sep 2016 Planned primary completion date changed from 1 May 2016 to 1 May 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top